Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Speech and language therapy effective for post-stroke aphasia
Vault Navigation
Speech and language therapy effective for post-stroke aphasia
How effective is speech and language therapy (SLT) for aphasia following stroke?
SLT benefitted functional use of language, language comprehension (eg, listening or reading) and language production (speaking or writing), when compared with no access to therapy, but it was unclear how long these benefits might last. Functional communication was significantly better in people with aphasia who received therapy at a high intensity (hours per week), high dose (total hours) or over a long duration compared with those who received therapy at a lower intensity, lower dose or over a shorter period. There was insufficient evidence to establish the effectiveness of one SLT theoretical approach over another, with little indication of a difference between group SLT versus one-to-one SLT, and computer-mediated SLT versus therapist-delivered SLT. Similarly, there was little indication of a difference in the effectiveness of SLT facilitated by a trained volunteer versus SLT delivered by a therapist.
The benefits of a high intensity or a high dose of SLT were confounded by a significantly higher dropout rate in these intervention groups.
Aphasia is an acquired language impairment following brain damage that affects some or all language modalities: expression and understanding of speech, reading and writing. Approximately one-third of people who have a stroke experience aphasia.
Brady MC et al. Speech and language therapy for aphasia following stroke. Cochrane Reviews, 2016, Issue 6. Art. No.: CD000425.DOI: 10.1002/14651858. CD000425.pub4. This review contains 57 studies involving 3002 participants.